Involvement of CX3CR1+ cells appearing in the abdominal cavity in the immunosuppressive environment immediately after gastric cancer surgery

Table 1 Clinicopathological characteristics (n=41)

Variables	N or median (range)	Variables		N or median (range)
Age [years old]	72 (43-89)	Hisological type
Sex		differentiated/ undifferentiated adenoca.		22/ 19
Male/ Female	31/10	Tumor Location^b
Body Mass Index [kg/m2]	21.97 (16.59-33.58)	E/ U/ M/ L/ Other		3/ 8/ 11/ 18/ 1
Other cancer history	14 (34.1%)	pT category^a
cT-category^a		1-2/ 3-4		16/ 25
1-2/ 3-4	13/ 28	pN-category^a
cN-category^a		0/ 1-3		19/ 22
0/ 1-3	20/ 21	pStage^a
cStage^a		I-II/ III-IV		26/ 15
I-II/ III-IV	21/ 20	Ly	present/ absent	18/ 23
Comorbidities (present, %)	35 (85.4%)	Vsss	present/ absent	17/ 24
Diabetes Mellitus	14 (34.1%)	Surgical operation
Cardiac disease	3 (7.31%)	Open/ Laparoscopy		31/ 10
Renal disorder	1 (2.44%)	TG/ DG+PG^b		14/ 27
Pulmonary disorder	6 (14.6%)	Lymph nodes dissection (D1/ 1+/ 2)		5/ 11/ 25
Hepatic disorder	6 (14.6%)	Bleeding [mL]		210 (5-1700)
		Operation time [min.]		259 (106-607)
		Anesthesia time [min.]		294 (148-640)
		Duration of hospitalization [days]		13 (8-64)

^aTNM Classification of Gastric cancer, 8th ed
^b Abbreviation: TG Total gastrectomy, DG Distal gastrectomy, PG Proximal gastrectomy
E Esophagogastoric, U Upper third gastric, M Middle third gastric, L Lower third gastric

ISSN: 1477-7819